Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synbio Tech's revenue for the
three
months ended in Jun. 2026 was NT$296 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,007 Mil.
Synbio Tech's Revenue per Share for the
three
months ended in Jun. 2026 was NT$8.56.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$29.05.
Warning Sign:
Synbio Tech Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Synbio Tech was -12.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Synbio Tech's highest 3-Year average Revenue per Share Growth Rate was 9.90% per year. The lowest was 3.60% per year. And the median was 4.60% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Synbio Tech Revenue Related Terms
Synbio Tech Revenue Historical Data
* Premium members only.
The historical data trend for Synbio Tech's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Synbio Tech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's Revenue distribution charts can be found below:
* The bar in red indicates where Synbio Tech's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,007 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synbio Tech (ROCO:1295) has a Revenue of NT$1,007 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Synbio Tech and its competitors.
Is Synbio Tech's Revenue too high?
Synbio Tech's current Revenue is NT$1,007 Mil. Overall, Synbio Tech has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's Revenue compare to VRTX and REGN?
Synbio Tech's Revenue of NT$1,007 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Synbio Tech and its competitors. Synbio Tech's current Revenue is NT$1,007 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Based on GuruFocus' analysis, Synbio Tech (ROCO:1295) is currently considered Possible Value Trap. The stock's GF Value™ is NT$82.54, compared to a current price of NT$45.30 — trading 45.1% below its estimated fair value. The current Revenue is NT$1,007 Mil. Synbio Tech's overall GF Score™ is 57/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current Revenue is NT$1,007 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synbio Tech (ROCO:1295) Overvalued in 2026?
Based on GuruFocus' analysis, Synbio Tech stock appears to be undervalued.
The current stock price of NT$45.30 is trading 45.1% below its estimated GF Value™ of NT$82.54.
GuruFocus considers Synbio Tech to be Possible Value Trap.
Key valuation signals for ROCO:1295:
Revenue: NT$1,007 Mil
GF Value™: NT$82.54 vs. price of NT$45.30 (45.1% below fair value)
No single metric tells the full story. See the ROCO:1295 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
57GF Score
Get the complete analysis for ROCO:1295
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
